Could a common anesthetic help prevent liver cancer from coming back?

NCT ID NCT07657897

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at whether adding lidocaine to standard sedation during radiofrequency ablation for liver cancer can reduce inflammation and lower the chance of the cancer returning. The researchers focus on a process called NETosis, which is linked to tumor growth and spread. One hundred people with small liver tumors (up to 3 cm) will be randomly assigned to receive either standard sedation or sedation plus lidocaine, and their outcomes will be tracked for one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lidocaine
What this could lead to
If lidocaine reduces NETosis and recurrence, it could offer a simple, low-cost way to improve outcomes after liver cancer ablation.
What could go wrong
This is a small, early-stage study (100 participants) testing a biomarker-driven idea; results may not confirm benefit, and lidocaine's effect on recurrence is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABLATION TECHNIQUES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • "Prof. Dr. Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania

    RECRUITING

    Cluj-Napoca, Cluj, 400394, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.